by Mark Curtis | Jun 23, 2016
Welcome to your deal review for the month of May. Intellia Therapeutics went public this past month giving investors a second shot on net if they want to gain exposure to gene editing technologies. Caladrius Biosciences spun-out its cell-based immunotherapy to AiVita...
by Stacey Johnson | Jun 3, 2016
Have you ever wanted to shed your skin? I don’t mean in the metaphorical sense like becoming a different person, free of all the old baggage we accumulate in life. And I’m not talking about CCRM’s new logo and colours either, but thanks for noticing. (Shameless.) I...
by Stacey Johnson | May 27, 2016
The subway map is a popular metaphor for showing how to get from point A to point B with many stops along the way. It can be simple, with only a few intersecting lines of tracks – Toronto’s (shockingly inadequate) two-line system comes to mind – or complicated, like...
by Paul Krzyzanowski | May 25, 2016
A few weeks ago, I came across an interesting story about a stem cell company with a peculiar patenting strategy. As I looked into it further, I realized I’d stumbled into a complicated corporate plot that became more incredible with every turn. Endonovo Therapeutics...
by Stacey Johnson | Apr 29, 2016
Jennifer Hicks at Forbes has written about a handheld surgical device that can draw stem cells to repair cartilage so that the damaged cartilage can heal itself with its own cells. How cool is that?! The ARC Centre of Excellence for Electromaterials Science in...
by Mark Curtis | Apr 28, 2016
Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and...
Comments